Advertisement

Symptoms during chemotherapy in colorectal cancer patients

  • Kari RöhrlEmail author
  • Marianne Grønlie Guren
  • Milada Cvancarova Småstuen
  • Tone Rustøen
Original Article

Abstract

Purpose

Colorectal cancer (CRC) patients experience several physical and psychological co-occurring symptoms, but little is known about symptom variation during chemotherapy cycles. Therefore, the aims were (1) to assess the occurrence and severity of frequently occurring symptoms (worrying, lack of energy, numbness/tingling, nausea, and pain) at multiple time points during chemotherapy, (2) to investigate differences in symptom trajectories between chemotherapy groups, and (3) to determine whether selected patient and clinical characteristics are associated with symptom severity throughout the treatment trajectory.

Methods

In total, 120 CRC patients receiving chemotherapy with curative or palliative intent completed the Memorial Symptom Assessment Scale (MSAS), Self-Administered Comorbidity Questionnaire (SCQ-19), and Karnofsky Performance Status (KPS) scale eight times, during two cycles of chemotherapy and 3 and 6 months after enrolment. Data were analyzed using linear mixed models for repeated measures to assess the effects of selected variables on outcomes over time.

Results

The patients experienced greatest symptom severity in the days following the administration of chemotherapy; these were lack of energy, numbness/tingling (oxaliplatin group), and nausea. Palliative patients reported significantly higher pain scores compared with curative patients over time, whereas the severity of worrying decreased over time in both treatment groups. Age, sex, educational level, performance status, treatment intent and type of chemotherapy were significantly associated with symptom severity throughout the chemotherapy trajectory.

Conclusion

Clinicians can use these findings to identify and inform patients about risk for more severe symptom burden, in order to offer supportive care at the right time during the chemotherapy treatment.

Keywords

Colorectal neoplasm Chemotherapy Symptoms Trajectory Longitudinal Memorial Symptom Assessment Scale 

Notes

Acknowledgments

The authors thank the patients for their valuable contribution to this study. Furthermore, we thank the study nurse Ms. Kolstad, and Oslo University Hospital, Oslo, for their help and facilitation, Mr. Pripp for his statistical advice at the early study process, and Mr. Horgmo and Ms. Ellefsen of the Medical Photography and Illustration Service, University of Oslo, for the valuable graphic support.

Funding

The Institute of Health and Society, Faculty of Medicine, Nursing Science, Oslo University supported this study, with additional grants from The Norwegian Nurses Organization.

Compliance with ethical standards

The Regional Ethical Committee (2009/1451), the Hospital Privacy Ombudsman, and the institutional review board at Oslo University Hospital approved the study.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108CrossRefGoogle Scholar
  2. 2.
    Pettersson G, Bertero C, Unosson M, Borjeson S (2014) Symptom prevalence, frequency, severity, and distress during chemotherapy for patients with colorectal cancer. Support Care Cancer 22(5):1171–1179CrossRefGoogle Scholar
  3. 3.
    Rohrl K, Guren MG, Miaskowski C, Cooper BA, Diep LM, Rustoen T (2016) No differences in symptom burden between colorectal Cancer patients receiving curative versus palliative chemotherapy. J Pain Symptom Manag 52(4):539–547CrossRefGoogle Scholar
  4. 4.
    Tantoy IY, Cooper BA, Dhruva A et al (2018) Changes in the occurrence, severity, and distress of symptoms in patients with gastrointestinal cancers receiving chemotherapy. J Pain Symptom Manag 55(3):808–834Google Scholar
  5. 5.
    Lee SE, Vincent C, Finnegan L (2017) An analysis and evaluation of the theory of unpleasant symptoms. ANS Adv Nurs Sci 40(1):E16–E39PubMedGoogle Scholar
  6. 6.
    Kristensen A, Solheim TS, Amundsen T et al (2017) Measurement of health-related quality of life during chemotherapy—the importance of timing. Acta Oncol 56(5):737–745Google Scholar
  7. 7.
    Giesinger JM, Wintner LM, Zabernigg A, Gamper EM, Oberguggenberger AS, Sztankay MJ, Kemmler G, Holzner B (2014) Assessing quality of life on the day of chemotherapy administration underestimates patients’ true symptom burden. BMC Cancer 14:758CrossRefGoogle Scholar
  8. 8.
    Foltran L, Aprile G, Pisa FE, Ermacora P, Pella N, Iaiza E, Poletto E, Lutrino SE, Mazzer M, Giovannoni M, Cardellino GG, Puglisi F, Fasola G (2014) Risk of unplanned visits for colorectal cancer outpatients receiving chemotherapy: a case-crossover study. Support Care Cancer 22(9):2527–2533CrossRefGoogle Scholar
  9. 9.
    Andre T, de Gramont A, Vernerey D et al (2015) Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J Clin Oncol 33(35):4176–4187CrossRefGoogle Scholar
  10. 10.
    Schmoll HJ, Van Cutsem E, Stein A et al (2012) ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 23(10):2479–2516CrossRefGoogle Scholar
  11. 11.
    Van Cutsem E, Cervantes A, Adam R et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27(8):1386–1422CrossRefGoogle Scholar
  12. 12.
    Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, Rogak L, Bennett AV, Dueck AC, Atkinson TM, Chou JF, Dulko D, Sit L, Barz A, Novotny P, Fruscione M, Sloan JA, Schrag D (2016) Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol 34(6):557–565CrossRefGoogle Scholar
  13. 13.
    Gensheimer SG, Wu AW, Snyder CF, Group P-EUGS, Group P-EUGW (2018) Oh, the places we’ll go: patient-reported outcomes and electronic health records. Patient 11:591–598.  https://doi.org/10.1007/s40271-018-0321-9 CrossRefPubMedGoogle Scholar
  14. 14.
    Cleeland CS, Zhao F, Chang VT, Sloan JA, O'Mara AM, Gilman PB, Weiss M, Mendoza TR, Lee JW, Fisch MJ (2013) The symptom burden of cancer: evidence for a core set of cancer-related and treatment-related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns study. Cancer 119(24):4333–4340CrossRefGoogle Scholar
  15. 15.
    Ventzel L, Jensen AB, Jensen AR, Jensen TS, Finnerup NB (2016) Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel. Pain 157(3):560–568CrossRefGoogle Scholar
  16. 16.
    Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M (2014) Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 155(12):2461–2470CrossRefGoogle Scholar
  17. 17.
    Walling AM, Weeks JC, Kahn KL, Tisnado D, Keating NL, Dy SM, Arora NK, Mack JW, Pantoja PM, Malin JL (2015) Symptom prevalence in lung and colorectal cancer patients. J Pain Symptom Manag 49(2):192–202CrossRefGoogle Scholar
  18. 18.
    Walker MS, Pharm EY, Kerr J, Yim YM, Stepanski EJ, Schwartzberg LS (2012) Symptom burden & quality of life among patients receiving second-line treatment of metastatic colorectal cancer. BMC Res Notes 5:314CrossRefGoogle Scholar
  19. 19.
    Vardy JL, Dhillon HM, Pond GR, Rourke SB, Bekele T, Renton C, Dodd A, Zhang H, Beale P, Clarke S, Tannock IF (2015) Cognitive function in patients with colorectal cancer who do and do not receive chemotherapy: a prospective, longitudinal, controlled study. J Clin Oncol 33(34):4085–4092CrossRefGoogle Scholar
  20. 20.
    Berger AM, Mitchell SA, Jacobsen PB, Pirl WF (2015) Screening, evaluation, and management of cancer-related fatigue: ready for implementation to practice? CA Cancer J Clin 65(3):190–211CrossRefGoogle Scholar
  21. 21.
    Tantoy IY, Cataldo JK, Aouizerat BE, Dhruva A, Miaskowski C (2016) A review of the literature on multiple co-occurring symptoms in patients with colorectal cancer who received chemotherapy alone or chemotherapy with targeted therapies. Cancer Nurs 39(6):437–445CrossRefGoogle Scholar
  22. 22.
    Berger AM, Grem JL, Visovsky C, Marunda HA, Yurkovich JM (2010) Fatigue and other variables during adjuvant chemotherapy for colon and rectal cancer. Oncol Nurs Forum 37(6):E359–E369CrossRefGoogle Scholar
  23. 23.
    Ripamonti C, Santini D, Maranzano E, Berti M, Roila F, Group EGW (2012) Management of cancer pain: ESMO clinical practice guidelines. Ann Oncol 23(Suppl 7):vii139–vii154CrossRefGoogle Scholar
  24. 24.
    Hilarius DL, Kloeg PH, van der Wall E, van den Heuvel JJ, Gundy CM, Aaronson NK (2012) Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. Support Care Cancer 20(1):107–117CrossRefGoogle Scholar
  25. 25.
    Schneider A, Kotronoulas G, Papadopoulou C, McCann L, Miller M, McBride J, Polly Z, Bettles S, Whitehouse A, Kearney N, Maguire R (2016) Trajectories and predictors of state and trait anxiety in patients receiving chemotherapy for breast and colorectal cancer: results from a longitudinal study. Eur J Oncol Nurs 24:1–7CrossRefGoogle Scholar
  26. 26.
    Astrup GL, Hofso K, Bjordal K et al (2017) Patient factors and quality of life outcomes differ among four subgroups of oncology patients based on symptom occurrence. Acta Oncol 56(3):462–470Google Scholar
  27. 27.
    Portenoy RK, Thaler HT, Kornblith AB, Lepore JM, Friedlander-Klar H, Kiyasu E, Sobel K, Coyle N, Kemeny N, Norton L (1994) The memorial symptom assessment scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 30A(9):1326–1336CrossRefGoogle Scholar
  28. 28.
    Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN (2003) The self-administered comorbidity questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum 49(2):156–163CrossRefGoogle Scholar
  29. 29.
    Schag CC, Heinrich RL, Ganz PA (1984) Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 2(3):187–193CrossRefGoogle Scholar
  30. 30.
    Brandenbarg D, Korsten J, Berger MY, Berendsen AJ (2018) The effect of physical activity on fatigue among survivors of colorectal cancer: a systematic review and meta-analysis. Support Care Cancer 26(2):393–403Google Scholar
  31. 31.
    Agasi-Idenburg SC, Thong MS, Punt CJ, Stuiver MM, Aaronson NK (2017) Comparison of symptom clusters associated with fatigue in older and younger survivors of colorectal cancer. Support Care Cancer 25(2):625–632CrossRefGoogle Scholar
  32. 32.
    Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-Snow RA, Dupuis LL, Einhorn LH, Feyer P, Hesketh PJ, Jordan K, Olver I, Rapoport BL, Roscoe J, Ruhlmann CH, Walsh D, Warr D, van der Wetering M, participants of the MASCC/ESMO Consensus Conference Copenhagen 2015 (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27(suppl 5):v119–v133CrossRefGoogle Scholar
  33. 33.
    Laugsand EA, Jakobsen G, Kaasa S, Klepstad P (2011) Inadequate symptom control in advanced cancer patients across Europe. Support Care Cancer 19(12):2005–2014CrossRefGoogle Scholar
  34. 34.
    Hofso K, Rustoen T, Cooper BA, Bjordal K, Miaskowski C (2013) Changes over time in occurrence, severity, and distress of common symptoms during and after radiation therapy for breast cancer. J Pain Symptom Manag 45(6):980–1006CrossRefGoogle Scholar
  35. 35.
    Gibson S, McConigley R (2016) Unplanned oncology admissions within 14 days of non-surgical discharge: a retrospective study. Support Care Cancer 24(1):311–317CrossRefGoogle Scholar
  36. 36.
    Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, Schrag D (2017) Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA 318:197–198CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Kari Röhrl
    • 1
    Email author
  • Marianne Grønlie Guren
    • 2
  • Milada Cvancarova Småstuen
    • 3
    • 4
  • Tone Rustøen
    • 1
    • 5
  1. 1.Department of Nursing Science, Institute of Health and Society, Faculty of MedicineUniversity of OsloOsloNorway
  2. 2.Department of Oncology and K.G. Jebsen Colorectal Cancer Research Centre, Cancer MedicineOslo University HospitalOsloNorway
  3. 3.National Advisory Unit on Late Effects after Cancer TreatmentOslo University HospitalOsloNorway
  4. 4.Faculty of Health SciencesOslo Metropolitan UniversityOsloNorway
  5. 5.Department of Research and Development, Division of Emergencies and Critical CareOslo University HospitalOsloNorway

Personalised recommendations